Literature DB >> 10374672

Significance of lymph node metastases in the surgical management of pancreatic head carcinoma.

G Benassai1, M Mastrorilli, F Mosella, G Mosella.   

Abstract

Recent reports have demonstrated a reduction in the morbidity and mortality of pancreatic resections and improvement in the 5-actuarial survival for patients with resected ductal adenocarcinoma. However, the prognosis for patients with lymph node metastases remains uncertain. The purpose of this study is to determine if the presence of lymph node metastases influences the survival in patients with otherwise potentially curable pancreatic head carcinoma. Between January 1974 and December 1995, 340 patients with pancreatic carcinoma, including 238 patients with pancreatic head tumours, were evaluated and treated in our Department. Seventy-seven (32.3%) patients with pancreatic head carcinoma underwent pancreaticoduodenectomy. Ages ranged from 40 to 76 years, with a mean age of 61 years. Fifty patients were male, twenty-seven were female. The overall postoperative mortality rate was 5.2% (4 patients) and morbidity was 23.4%. Median survival following resection was 17 months (range 0 to 79). The estimated 1-, 2-, 3- and 5-year survival were 68.8%, 48.1%, 23.4% and 18.2%, respectively. There were 14 five-year survivors. Of the 77 patients, 25 (32.5%) had negative lymph nodes. The median and 5-year survival in these node-negative patients were 33 months (range 5 to 79) and 40%, respectively. Whereas the median survival and 5-year survival in 52 patients with lymph nodes metastases were 14 months (range 0 to 61) and 7.7%, respectively (P<0.0001). There were 4 five-year survivors in the group of patients with lymph node metastases; in 2 patients was performed extensive lymph node dissection (R2) and in other 2 patients R1 procedure. In the patients with lymph node metastases undergoing R1 resection (n = 39), the 1-, 2- and 5-year survival rates were 48.7%, 23.1% and 5.1%, respectively. Whereas in the patients with positive lymph nodes undergoing R2 resection (n = 14), the 1-, 2- and 5-year survival rates were 92.9%, 64.3% and 14.3%, respectively (P<0.02). As expected, tumour size and margin status in specimen proved to be two significant factors predicting survival. Pancreatoduodenectomy can be performed with low operative mortality. Lymph nodes metastases are found in 67.5% of patient undergoing resection. Pancreaticoduodenectomy offers good palliation for patients with lymph nodes metastases and encouraging long-term survival rates as well as a chance for cure in patients with negative lymph nodes and negative margins of resection.

Entities:  

Mesh:

Year:  1999        PMID: 10374672

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  14 in total

1.  Extended pancreatic resections and lymphadenectomy: An appraisal of the current evidence.

Authors:  Shailesh V Shrikhande; Savio G Barreto
Journal:  World J Gastrointest Surg       Date:  2010-02-27

Review 2.  The lymphatic system and pancreatic cancer.

Authors:  Darci M Fink; Maria M Steele; Michael A Hollingsworth
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

3.  Improved lymph node retrieval in Whipple specimens as a result of implementation of a new uncinate margin protocol.

Authors:  Corwyn H Rowsell; Sherif Hanna; Eugene Hsieh; Calvin Law; Mahmoud A Khalifa
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

4.  Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio.

Authors:  Bolanle Asiyanbola; Ana Gleisner; Joseph M Herman; Michael A Choti; Christopher L Wolfgang; Michael Swartz; Barish H Edil; Richard D Schulick; John L Cameron; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2008-12-17       Impact factor: 3.452

5.  Prognostic value of the lymph node ratio after resection of periampullary carcinomas.

Authors:  Shahid G Farid; Gavin A Falk; Daniel Joyce; Sricharan Chalikonda; R Matthew Walsh; Andrew M Smith; Gareth Morris-Stiff
Journal:  HPB (Oxford)       Date:  2012-11-19       Impact factor: 3.647

6.  Improving Survival of Pancreatic Cancer. What Have We Learnt?

Authors:  Tanveer Singh; Adarsh Chaudhary
Journal:  Indian J Surg       Date:  2015-10-22       Impact factor: 0.656

7.  Prognostic value of SUVmax measured by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography in Patients with Pancreatic Cancer.

Authors:  Jae Pil Hwang; Ilhan Lim; Kyoung Jin Chang; Byung Il Kim; Chang Woon Choi; Sang Moo Lim
Journal:  Nucl Med Mol Imaging       Date:  2012-06-30

8.  Cost-utility estimation of surgical treatment of pancreatic carcinoma aimed at cure.

Authors:  David Ljungman; Kent Lundholm; Anders Hyltander
Journal:  World J Surg       Date:  2011-03       Impact factor: 3.352

9.  Relationship between expression of E-cadherin-catenin complex and clinicopathologic characteristics of pancreatic cancer.

Authors:  Yu-Jun Li; Xiang-Rui Ji
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

10.  The number of lymph nodes identified in a simple pancreatoduodenectomy specimen: comparison of conventional vs orange-peeling approach in pathologic assessment.

Authors:  N Volkan Adsay; Olca Basturk; Deniz Altinel; Fayyaz Khanani; Ipek Coban; Donald W Weaver; David A Kooby; Juan M Sarmiento; Charles Staley
Journal:  Mod Pathol       Date:  2008-09-26       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.